Literature DB >> 22060084

Practical neurology--4: Dizziness on head movement.

Miriam S Welgampola1, Andrew Bradshaw, G Michael Halmagyi.   

Abstract

Benign positional vertigo (BPV) is the most common cause of episodic vertigo. It results from activation of semicircular canal receptors by the movement of calcium carbonate particles (otoconia) which dislodge from the otolith membranes. During changes in head position, the otoconia either float freely within the semicircular canal duct (canalithiasis) or adhere to and move with the cupula of the canal (cupulolithiasis). BPV from canalithiasis evokes brief spells of vertigo lasting seconds and can be diagnosed at the bedside by provoking paroxysmal vertigo and nystagmus on tilting the head in the plane of the affected canal. The nystagmus has a unique rotational axis perpendicular to the affected canal. The Dix-Hallpike test is a simple means of confirming the diagnosis in patients presenting with episodic vertigo or imbalance. Audiovestibular tests are only indicated if a symptomatic primary underlying inner ear disease is suspected. In over 80% of patients, BPV can be treated successfully with a single bedside Epley (particle-repositioning) manoeuvre, which can be performed by any medical practitioner.

Entities:  

Mesh:

Year:  2011        PMID: 22060084     DOI: 10.5694/mja11.11001

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  2 in total

1.  Immunogold TEM of otoconin 90 and otolin - relevance to mineralization of otoconia, and pathogenesis of benign positional vertigo.

Authors:  Leonardo R Andrade; Ulysses Lins; Marcos Farina; Bechara Kachar; Ruediger Thalmann
Journal:  Hear Res       Date:  2012-07-25       Impact factor: 3.208

2.  In vitro calcite crystal morphology is modulated by otoconial proteins otolin-1 and otoconin-90.

Authors:  K Trent Moreland; Mina Hong; Wenfu Lu; Christopher W Rowley; David M Ornitz; James J De Yoreo; Ruediger Thalmann
Journal:  PLoS One       Date:  2014-04-18       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.